Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 555

1.
2.

Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.

Jakubiak-Wielganowicz M, Kubiak R, Sygut J, Pomorski L, Kordek R.

Pol J Pathol. 2003;54(2):111-5.

PMID:
14575419
3.

Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.

Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M.

Hum Pathol. 2008 Nov;39(11):1656-63. doi: 10.1016/j.humpath.2008.04.006. Epub 2008 Jul 26.

PMID:
18657294
4.

Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal.

Liu Z, Zhou G, Nakamura M, Koike E, Li Y, Ozaki T, Mori I, Taniguchi E, Kakudo K.

Cancer Sci. 2011 Jan;102(1):288-94. doi: 10.1111/j.1349-7006.2010.01769.x. Epub 2010 Nov 10.

5.

Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma.

Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Yasuoka H, Kakudo K, Inohara H, Kuma K, Miyauchi A.

Pathology. 2005 Aug;37(4):296-8.

PMID:
16194828
6.

Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.

Torregrossa L, Faviana P, Camacci T, Materazzi G, Berti P, Minuto M, Elisei R, Vitti P, Miccoli P, Basolo F.

Hum Pathol. 2007 Oct;38(10):1482-8. Epub 2007 Jun 26.

PMID:
17597183
7.

Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.

Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S.

Diagn Cytopathol. 2004 Dec;31(6):392-6.

PMID:
15540177
8.

Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.

Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, Stern Y.

Head Neck. 2004 Nov;26(11):960-6.

PMID:
15386597
9.

Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland.

Gaffney RL, Carney JA, Sebo TJ, Erickson LA, Volante M, Papotti M, Lloyd RV.

Am J Surg Pathol. 2003 Apr;27(4):494-8.

PMID:
12657934
10.

Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.

Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, Zhu X.

J Clin Pathol. 2010 Sep;63(9):786-9. doi: 10.1136/jcp.2010.076901. Epub 2010 Jul 19.

PMID:
20644217
11.

Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.

Mai KT, Landry DC, Thomas J, Burns BF, Commons AS, Yazdi HM, Odell PF.

Histopathology. 2001 Jul;39(1):25-32.

PMID:
11454041
12.

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.

Abd-El Raouf SM, Ibrahim TR.

Pathol Res Pract. 2014 Dec;210(12):971-8. doi: 10.1016/j.prp.2014.06.010. Epub 2014 Jun 27.

PMID:
25041837
13.

[Expression of galectin-3 in thyroid gland and follicular cell tumors of the thyroid. A critical study of its possible role in preoperative differential diagnosis].

Niedobitek C, Niedobitek F, Lindenberg G, Bachler B, Neudeck H, Zuschneid W, Hopfenmüller W.

Pathologe. 2001 May;22(3):205-13. German.

PMID:
11402851
14.

Galectin-3 is a presurgical marker of human thyroid carcinoma.

Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A.

Cancer Res. 1998 Jul 15;58(14):3015-20.

15.

HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.

Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A.

Anticancer Res. 2005 Jan-Feb;25(1A):179-82.

16.

Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia.

Coli A, Bigotti G, Zucchetti F, Negro F, Massi G.

Histopathology. 2002 Jan;40(1):80-7.

PMID:
11903601
17.

Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.

Coli A, Bigotti G, Parente P, Federico F, Castri F, Massi G.

J Exp Clin Cancer Res. 2007 Jun;26(2):221-7.

PMID:
17725102
18.
19.

Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.

Mataraci EA, Ozgüven BY, Kabukçuoglu F.

Pol J Pathol. 2012 Mar;63(1):58-64.

20.

Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M.

Endocr Relat Cancer. 2005 Jun;12(2):305-17.

Supplemental Content

Support Center